Trifocal Diffractive Intraocular Lens After Cataract Extraction With Phacoemulsification

Sponsor
Alexandria University (Other)
Overall Status
Completed
CT.gov ID
NCT04465279
Collaborator
(none)
36
1
1
20
1.8

Study Details

Study Description

Brief Summary

Multifocal IOLs that maintain distance focus and improve near vision have been developed to reduce spectacle dependence.Multifocal IOLs improve patient performance of near-vision tasks, such as reading crafts, hobbies, and social activities to a greater extent than do monofocal IOLs. However, halos and reduced contrast sensitivity have been associated with multifocal IOLs and are common reasons for patient's dissatisfaction.Trifocal technology has been developed to create intermediate focus to overcome these difficulties. Continuous reports of the visual outcomes of the FineVision trifocal IOLs are encouraging.

Condition or Disease Intervention/Treatment Phase
  • Device: Trifocal diffractive intraocular lens
Phase 2/Phase 3

Detailed Description

Monofocal IOLs, which provide effective distance vision, currently account for the majority of IOLs implantations. Patients who have undergone cataract surgery with implantation of monofocal IOL may require spectacles to perform near-distance (e.g., reading) or intermediate-distance (e.g., using a computer) tasks depending on their visual demandsMultifocal IOLs that maintain distance focus and improve near vision have been developed to reduce spectacle dependence.Multifocal IOLs improve patient performance of near-vision tasks, such as reading crafts, hobbies, and social activities to a greater extent than do monofocal IOLs. However, halos and reduced contrast sensitivity have been associated with multifocal IOLs and are common reasons for patient's dissatisfaction.Trifocal technology has been developed to create intermediate focus to overcome these difficulties. Continuous reports of the visual outcomes of the FineVision trifocal IOLs are encouraging.

Study Design

Study Type:
Interventional
Actual Enrollment :
36 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This is a prospective, non-comparative, non-randomized study including 36 eyes had implantation of trifocal diffractive IOLThis is a prospective, non-comparative, non-randomized study including 36 eyes had implantation of trifocal diffractive IOL
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of Trifocal Diffractive Intraocular Lens After Cataract Extraction With Phacoemulsification
Actual Study Start Date :
Oct 15, 2018
Actual Primary Completion Date :
May 15, 2020
Actual Study Completion Date :
Jun 15, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Trifocal Diffractive Intraocular Lens (FineVision)

36 eyes having implantation of trifocal diffractive IOL (FineVision)

Device: Trifocal diffractive intraocular lens
Trifocal IOL having foldable single-piece fully diffractive pupil dependent aspheric IOL. Which have been made of hydrophilic acrylic with an ultraviolet (UV) and blue light inhibitor. It has an optic diameter of 6.15 mm and an overall diameter of 10.75 mm; it has +3.5D additional power for near vision and +1.75 D additional power for intermediate vision, consisting of 26 diffractive steps.
Other Names:
  • (FineVision IOL)
  • Outcome Measures

    Primary Outcome Measures

    1. Visual Acuity [3 months]

      Current study used Sloan chart (Good - Lite Co, USA) for intermediate, Snellen chart for far and Landolt ring chart for near vision

    2. Defocus curve [3 months]

      examined monocular and binocular after correcting distant VA refractive error then inserting defocus lenses 0.50-D focus steps from (+1.50 to -3.50 D) in the trial frame

    Secondary Outcome Measures

    1. Contrast sensitivity [3 months]

      using the CSV-1000 contrast test.

    2. Visual Satisfaction Questionnaire [3 months]

      Questionnaire patient satisfaction protocol mediated by (PhysIOL Lige, Belgium).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patient eyes had cataract with no other pathology, patients desire for spectacle independence after surgery and with realistic expectation.
    Exclusion Criteria:
    • Any ocular comorbidity that affect the end results of the surgery, history of ocular trauma, irregular corneal astigmatism, pupil abnormalities and capsular or zonular abnormalities that may affect postoperative centration as tilt of the lens (e.g. pseudo exfoliation syndrome and Marfan's syndrome).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Alexandria Faculty of Medicine Alexandria Egypt

    Sponsors and Collaborators

    • Alexandria University

    Investigators

    • Principal Investigator: Ehab Mossallam, PhD, Alexandria Faculty of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Alexandria University
    ClinicalTrials.gov Identifier:
    NCT04465279
    Other Study ID Numbers:
    • 0000755
    First Posted:
    Jul 10, 2020
    Last Update Posted:
    Jul 10, 2020
    Last Verified:
    Jun 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 10, 2020